BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 20, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Feb. 13, 2009
View Archived Issues
Portola's Anticlotting Drug Gains Partner in Potential $575M Deal
In its first major collaboration, privately held Portola Pharmaceuticals Inc. partnered one of its two lead antithrombotic programs with Novartis AG in a deal potentially worth up to $575 million. (BioWorld Today)
Read More
Futility Analysis Derails BioMarin and LJP's Phase III Riquent Trial
Read More
Better Blood Supply Leads to Better-Behaved Tumors
Read More
Insmed Jumps on Merck $130M Bid for FOBs Drugs
Read More
Holiday Notice
Read More
Corrections & Clarifications
Read More
Alios Closes $8.4M Tranche of $24M Series A Round
Read More
Oscient and Telik Cut Deep to Conserve Capital
Read More
Novelos, Mundipharma Sign $95M Deal for Cancer Drug
Read More
Appointments And Advancements
Read More
Other News To Note
Read More
Clinic Roundup
Read More